(NASDAQ: AVTX) Avalo Therapeutics's forecast annual revenue growth rate of 31.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Avalo Therapeutics's revenue in 2025 is $441,000.On average, 1 Wall Street analysts forecast AVTX's revenue for 2029 to be $471,699,483, with the lowest AVTX revenue forecast at $471,699,483, and the highest AVTX revenue forecast at $471,699,483. On average, 3 Wall Street analysts forecast AVTX's revenue for 2030 to be $1,615,869,543, with the lowest AVTX revenue forecast at $76,411,047, and the highest AVTX revenue forecast at $3,501,248,107.
In 2031, AVTX is forecast to generate $3,724,825,124 in revenue, with the lowest revenue forecast at $687,912,866 and the highest revenue forecast at $6,761,737,382.